Page last updated: 2024-11-07

lysyllysine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lysyllysine: RN given refers to (L-Lys)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Lys-Lys : A dipeptide formed from two L-lysine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID128837
CHEMBL ID379332
CHEBI ID74564
SCHEMBL ID1070057
MeSH IDM0082962

Synonyms (29)

Synonym
2RKM
bdbm50188512
lysyllysine
lys-lys
13184-13-9
chebi:74564 ,
CHEMBL379332 ,
l-lysyl-l-lysine
(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoic acid
l-lysine, l-lysyl-
96ter1jroc ,
l-lysine, n(2)-l-lysyl-
unii-96ter1jroc
l-lys-l-lys
dilysine
h-l-lys-l-lys-oh
lysyl-lysine
h-lys-lys-oh
kk
SCHEMBL1070057
AKOS025405096
k-k dipeptide
lysine-lysine dipeptide
lysine lysine dipeptide
kk dipeptide
DTXSID00927364
n~2~-(2,6-diamino-1-hydroxyhexylidene)lysine
Q27144740
(s)-6-amino-2-((s)-2,6-diaminohexanamido)hexanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Oligo-peptide Binding ProteinSalmonella enterica subsp. enterica serovar TyphimuriumKi125.0000125.0000125.0000125.0000AID977610
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)10,900.00000.18000.19000.2000AID266249
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)10,900.00000.00020.660310.0000AID266249
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki96.00003.00006.47788.5000AID681124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID1811Experimentally measured binding affinity data derived from PDB1997Biochemistry, Aug-12, Volume: 36, Issue:32
Peptide binding in OppA, the crystal structures of the periplasmic oligopeptide binding protein in the unliganded form and in complex with lysyllysine.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1997Biochemistry, Aug-12, Volume: 36, Issue:32
Peptide binding in OppA, the crystal structures of the periplasmic oligopeptide binding protein in the unliganded form and in complex with lysyllysine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (6.25)18.7374
1990's10 (20.83)18.2507
2000's18 (37.50)29.6817
2010's16 (33.33)24.3611
2020's1 (2.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (98.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]